Trial · NCT04381936
Randomised Evaluation of COVID-19 Therapy
NCT04381936, Phase 3, Recruiting, University of Oxford
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Randomised Evaluation of COVID-19 Therapy. Trials, record NCT04381936. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04381936
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Randomised Evaluation of COVID-19 Therapy
- NCT number
- NCT04381936
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 70,000 participants, estimated
- Lead sponsor
- University of Oxford
- Conditions
- Pneumonia
- Interventions
Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine, Azithromycin, Convalescent plasma, Tocilizumab, Immunoglobulin, Synthetic neutralising antibodies, Aspirin, Colchicine, Baricitinib, Anakinra, Dimethyl fumarate, High Dose Corticosteroid, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid, Baloxavir Marboxil, Oseltamivir, Corticosteroids (dexamethasone), Corticosteroids (dexamethasone)
- First posted
- 2020-05-11
- Last updated
- 2026-04-21
- Other registries' IDs
- eudract:2020-001113-21, isrctn:ISRCTN50189673
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Community-acquired pneumonia: All-cause mortality (with subsidiary analyses of cause of death and of death at various timepoints following discharge) | Within 28 days after randomisation | For each pairwise comparison with the 'no additional treatment' arm, the primary objective is to provide reliable estimates of the effect of study treatments on all-cause mortality. |
| Primary | Influenza co-primary outcome: All-cause mortality (with subsidiary analysis of cause of death and death at various timepoints following discharge) | Within 28 days after randomisation | |
| Primary | Influenza co-primary outcome: Time to discharge alive from hospital | Within the first 28-days | |
| Secondary | Community-acquired pneumonia: Duration of hospital stay | Within 28 days and up to 6 months after the main randomisation | To assess the effects of study treatment on number of days stay in hospital |
| Secondary | Community-acquired pneumonia: Composite endpoint of death or need for mechanical ventilation or ECMO | Within 28 days and up to 6 months after the main randomisation | Among patients not on invasive mechanical ventilation at baseline, the number of patients with a composite endpoint of death or need for invasive mechanical ventilation or ECMO. |
| Secondary | Influenza: Composite endpoint of death or need for mechanical ventilation or ECMO | Within 28 days and up to 6 months after the main randomisation | Among patients not on invasive mechanical ventilation at baseline, the number of patients with a composite endpoint of death or need for invasive mechanical ventilation or ECMO. |
| Other | Need for (and duration of) ventilation | Within 28 days and up to 6 months after the main randomisation | To assess the effects of study treatment on number of patients who needed any ventilation and (for invasive mechanical ventilation) the number of days it was required |
| Other | Need for renal replacement | Within 28 days and up to 6 months after the main randomisation | To assess the effects of study treatment on number of patients who needed renal replacement therapy |
| Other | Number of patients who had thrombotic events | Within 28 days and up to 6 months after the main randomisation | To assess the effects of study treatment on number of patients who had thrombotic events, defined as either (i) acute pulmonary embolism; (ii) deep vein thrombosis; (iii) ischaemic stroke; (iv) myocardial infarction; or (v) systemic arterial embolism. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers28
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04381936
GET https://conductscience.org/api/trials/v1/NCT04381936/papers?page=2